NAC: Uncategorized

First Lady salutes NAC for donating cancer machines

Tendai Rupapa Senior Reporter
Health and Child Care Ambassador, First Lady Auxillia Mnangagwa yesterday commended the National Aids Council of Zimbabwe for donating cervical cancer screening machines to the Ministry of Health and Child Care.
TruScreen-Ultra cervical cancer screening machines, which were procured by NAC and its partners through funds raised from a golf tournament, resonate well with the First Lady’s work on cancer which has seen her traversing the country advising women on the need for screening and early treatment of the disease.
Speaking at the handover of the machines, the First Lady said: “These machines will complement already available national services while also expanding health care as they have multi-purpose capabilities such as screening and management of pregnancy and heart conditions.
“The NAC 2019 HIV, AIDS and cancer prevention golf drive is a noble initiative whose results we have already witnessed through the handing over of 16 cervical cancer screening machines that were procured through funds raised from the previous golf tournament.

“This tournament is special in that it also underlines the importance of integrating HIV and cancer services.”
The First Lady took the opportunity to officially launch this year’s National Aids Council HIV, AIDS and cancer prevention golf drive.
She appealed to captains of industry and development partners to participate in the tournament and donate to the cause of women.
Amai Mnangagwa said it was pleasing that women will be participating in the tournament.

Health and Child Care Minister Dr Obadiah Moyo welcomed the donation from NAC and commended the First Lady for leading the promotion of good health among citizens, particularly adolescent girls and women.
“The First Lady has deep passion in provision of services to control HIV and cervical cancer among women and children as well as eradication of child marriages.
“This handover of machines therefore blends with her work as it comes in the midst of a spike in the cases of cancer among our people, which demands urgent intervention before the situation reaches epidemic levels.
“I want to thank NAC for the golf tournament resource mobilisation strategy through which the funds to procure these machines were raised.”
The First Lady’s cancer awareness campaigns across the country have seen thousands of women undergoing cervical cancer screening.

NAC Fund Raising Golf Tournament Pays Off

NAC fundraising golf tournament pays off as The First Lady of Zim H.E A Mnangagwa Zimbabwe Health Ambassador hands over 16 cancer screening machines bought with proceeds from the 2018 golf tournament to Ministry of Health and Child Care at Chapman Golf Club in Harare this afternoon.

The cancer machines were bought with support from New Avakash, Medirite Distribution, PSMI, FBC Agribank CBZ,POSB and Southern Skies will be distributed to selected 16 rural health centres.

The First Lady of Zimbabwe H.E A Mnangagwa on the same occasion officially launched the 2019 NAC Fundraising Golf Tournament which will take place at Chapman Golf Club from 16-17 October, which is aimed at raising resources to procure more cancer screening machines.

 

Second man seems to be free of AIDS virus after transplant

SEATTLE (AP) – A London man appears to be free of the AIDS virus after a stem cell transplant, the second success including the “Berlin patient,” doctors reported.
The therapy had an early success with Timothy Ray Brown, a U.S. man treated in Germany who is 12 years post-transplant and still free of HIV. Until now, Brown is the only person thought to have been cured of infection with HIV, the virus that causes AIDS.
Such transplants are dangerous and have failed in other patients. They’re also impractical to try to cure the millions already infected.

The latest case “shows the cure of Timothy Brown was not a fluke and can be recreated,” said Dr. Keith Jerome of Fred Hutchinson Cancer Research Center in Seattle who had no role. He added that it could lead to a simpler approach that could be used more widely.
The case was published online Monday by the journal Nature and will be presented at an HIV conference in Seattle.
The patient has not been identified. He was diagnosed with HIV in 2003 and started taking drugs to control the infection in 2012. It’s unclear why he waited that long. He developed Hodgkin lymphoma that year and agreed to a stem cell transplant to treat the cancer in 2016.
With the right kind of donor, his doctors figured, the London patient might get a bonus beyond treating his cancer: a possible HIV cure.
Doctors found a donor with a gene mutation that confers natural resistance to HIV. About 1 percent of people descended from northern Europeans have inherited the mutation from both parents and are immune to most HIV. The donor had this double copy of the mutation.

That was “an improbable event,” said lead researcher Ravindra Gupta of University College London. “That’s why this has not been observed more frequently.”
The transplant changed the London patient’s immune system, giving him the donor’s mutation and HIV resistance.
The patient voluntarily stopped taking HIV drugs to see if the virus would come back.
Usually, HIV patients expect to stay on daily pills for life to suppress the virus. When drugs are stopped, the virus roars back, usually in two to three weeks.
That didn’t happen with the London patient. There is still no trace of the virus after 18 months off the drugs.
Brown said he would like to meet the London patient and would encourage him to go public because “it’s been very useful for science and for giving hope to HIV-positive people, to people living with HIV,” he told The Associated Press Monday.
Stem cell transplants typically are harsh procedures which start with radiation or chemotherapy to damage the body’s existing immune system and make room for a new one. There are complications too. Brown had to have a second stem cell transplant when his leukemia returned.
Compared to Brown, the London patient had a less punishing form of chemotherapy to get ready for the transplant, didn’t have radiation and had only a mild reaction to the transplant.
Dr. Gero Hutter, the German doctor who treated Brown, called the new case “great news” and “one piece in the HIV cure puzzle.”

HIV Drugs Market Size Outlook 2027: Top Companies, Trends, Growth Factors Details by Regions, Distribution Channel and Medication Class

Sep 03, 2019 (AmericaNewsHour) — The global HIV drugs market can be segmented on the basis of distribution channel, medication class and region. Based on distribution channel, it is sub-segmented into retail, online and hospital pharmacies among others. On the basis of medication class, it is sub-segmented into nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), multiclass combination drugs, protease inhibitors, fusion inhibitors and HIV integrase strand transfer inhibitors, out of which, the multi class combination drugs is anticipated to have the largest market share in the market as it is the most recent method to treat HIV/AIDS. The main focus of the key players in this industry is to reduce the number of HIV/AIDS population and thereby reducing the deaths which in turn is anticipated to boost the market shares during the forecast period.

The global HIV drugs market is anticipated to expand at a CAGR around 3.8% during the forecast period i.e. 2019-2027. Increase in the initiatives taken by the government and organizations to enhance awareness among people about HIV/AIDS is driving the growth of the market. Further, the rising number of AIDS patients across the globe coupled with huge investments in the field of research and development for HIV drugs and various advancements in the healthcare sector are the prime reasons that are driving the growth of the market.
Geographically, the global HIV drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Among these regions, North America region is anticipated to have half of the share of the HIV drug market which can be attributed to higher expenditure of the government on research and development, increment in the adoption of advanced therapy and treatment options and also because of the well-established healthcare sector. Asia Pacific region is also anticipated to show a vibrant growth over the forecast period. This is due to the lack of awareness among people about protected sex and sex education in the developing areas.

he report titled “HIV Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” delivers the detailed overview of the global HIV drugs market in terms of market segmentation by product, by end-users and by region.
Request a sample Report of HIV Drugs Market at:https://www.researchnester.com/sample-request-1353
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model. This report also provides the existing competitive scenario of some of the key players of the global HIV drugs market which includes company profiling of key companies such as Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Cipla Limited, Boehringer Ingelheim International GmbH. The outlining enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global HIV drugs market that is expected to help industry consultants, equipment manufacturers, existing players searching for expansion new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

 

UN appoints new HIV and AIDS chief

United Nations (United States) (AFP) – United Nations Secretary General Antonio Guterres appointed a new HIV/AIDS chief on Wednesday.

Oxfam International executive director Winnie Byanyima of Uganda will lead UNAIDS, a spokesperson for Guterres said in a statement. She succeeds Michel Sidibe who stepped down in May.

In the statement announcing Byanyima’s appointment, Guterres said she “brings a wealth of experience and commitment in harnessing the power of government, multilateral agencies, the private sector and civil society to end the HIV and AIDS crisis for communities around the world.”

Byanyima, 60, said she was “honored” to be joining UNAIDS “at such a critical time in the response to HIV.”

Developing story.

Zimbabwe: First Lady Backs Zim Men’s Paternity Leave Demands

By Robert Tapfumaneyi
First Lady Auxillia Mnangagwa says Zimbabwean men demanding to be accorded the right to also go on paternity leave to look after their newly born offspring must be prepared to take the responsibilities that come with the holiday.
She was speaking at the inaugural Health Men’s Conference that was organised by the National Aids Council (NAC) in Harare Wednesday.
“Men need to promise me that if you are given paternity leave, you will not disappear from your wives, only to appear after two weeks with lame excuses,” she said.
This comes amid growing demands by men to be also afforded rights to be absent from work to mind their offspring.
The men said this will allow them time to bond with their newly born babies.
Stanford Chimutimunzveve, an advisory board committee member of College of Health Sciences University of Zimbabwe (UZ), said participation of men in some health and family issues is low in the country because of some preventative policies, as men do not get paternity leave.
“I think there are other factors that lead to this,” he said at the event.

“If we look at some polices in this country, men do not have paternity leave from our various work places.”

Auxillia Mnangagwa also challenged some MPs who were part of the event to ensure the contentious issue, as was the case with many other concerns, must be discussed at policy level.
“We are going to lobby for men to have paternity leave from their work places. This has never happened in this country,” she said to a round of applause.
“Paternity leave should be an opportunity for men to learn more about pregnancy and child bearing, spend time with your wives until the child is born.
“Yes as women, we need our husbands during this time because there are times that we are unable to do some chores and you wish your husband were there to help.
“But if you (men) disappear and come back after some time, paternity leave will not add value to your wives and family, and once Parliament has approved and passed the Bill, it’s not a ticket for men to run away from their families and spend time with friends.”
NAC communications manager Tadiwa Pfukwa said the inaugural health men’s conference was meant to give participants the platform to highlight issues that affect their health seeking behaviour.